Endocrine system

MRI Reveals Significant Brain Abnormalities Post-COVID

Retrieved on: 
Monday, November 21, 2022
Health, Taste, Anxiety, Pectus carinatum, Fatigue, Society, Cerebral cortex, Sleep, Calcium, Doctor of Philosophy, White matter, Heart, Sensation, Infection, Lightheadedness, Radiology, Coronavirus, Survivor, Brain, Endocrine system, Brainstem, Report, Depression, RSNA, Education, Research, Patient, Blood, COVID-19, Radiological Society of North America, Smell, Stroke, Radiation, MRI, Indian Institutes of Technology, Headache, Iron, Insomnia, Frontal lobe, Attention, Disease, Calcification, Hormone, Medical imaging, Pharmaceutical industry, COVID

For this study, researchers used susceptibility-weighted imaging to analyze the effects that COVID-19 has on the brain.

Key Points: 
  • For this study, researchers used susceptibility-weighted imaging to analyze the effects that COVID-19 has on the brain.
  • "Our study highlights this new aspect of the neurological effects of COVID-19 and reports significant abnormalities in COVID survivors."
  • The researchers also found a significant difference in the right ventral diencephalon region of the brain stem.
  • The researchers are conducting a longitudinal study on the same patient cohort to determine whether these brain abnormalities persist over a longer time frame.

H.I.G. Capital Acquires Morningside Healthcare and Morningside Pharmaceuticals

Retrieved on: 
Monday, October 3, 2022
Professional Services, Medical Devices, Health, Finance, General Health, Pharmaceutical, CNS, CLO, International, Endocrine system, CEO, BDC, NHS, Growth, H.I.G. Capital, LLP, LLC, Â, Patient, Investment, Whitehorse, Fine chemical, Pharmaceutical industry, Gastroenteritis, Psychiatry, Aspire, Health care

), a leading global alternative investment firm with over $50 billion of equity capital under management, is pleased to announce that its portfolio company Aspire Pharma has acquired Morningside Healthcare and Morningside Pharmaceuticals (together Morningside or the Company), a leading UK provider of niche generic and branded specialty pharmaceuticals.

Key Points: 
  • ), a leading global alternative investment firm with over $50 billion of equity capital under management, is pleased to announce that its portfolio company Aspire Pharma has acquired Morningside Healthcare and Morningside Pharmaceuticals (together Morningside or the Company), a leading UK provider of niche generic and branded specialty pharmaceuticals.
  • Morningside, established in 1991 in the UK, is focused on developing and licensing niche generic pharmaceutical products.
  • Richard Condon (CEO, Aspire) remarked, We are excited to welcome the Morningside team to the Aspire family.
  • European Middle Market and Head of Healthcare in Europe, added, A combined Aspire and Morningside bring greater scale, breadth and diversity across products, geographies, and sales channels.

Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial

Retrieved on: 
Monday, September 12, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Symptoms of COVID-19, Corticobasal degeneration, Central nervous system, Therapy, Time, Endocrine system, Common, ATEC, Child, COVID-19, Brain, Finger, Blood, Hormone, Traditional Chinese medicine, Norepinephrine, Company, Headache, Thrombus, Private Securities Litigation Reform Act, ADHD, TCM, Industry, Program, Patient, VADRS, Irritability, CEO, Constipation, Quality of life, Female, Lists of diseases, Disorder, Excoriation disorder, Dopamine, Melatonin, Perception, Annual report, Caregiver, Behavior, Heart, Research, Parent, US Foods, ASD, Awareness, Tongue, Infection, Pharmaceutical industry, Medicine, Risk management, Medical device, Medical imaging, ASEAN

Regencell Bioscience Holdings Limited (Nasdaq: RGC) (Regencell) today announced its interim results from its second efficacy trial.

Key Points: 
  • Regencell Bioscience Holdings Limited (Nasdaq: RGC) (Regencell) today announced its interim results from its second efficacy trial.
  • Regencell conducted its second efficacy trial using standardized Traditional Chinese Medicine (TCM) formulae.
  • Our aim is to save and improve lives by making our standardized TCM formulae widely available to ADHD and ASD patients around the world.
  • Regencell standardized TCM formulae are natural, orally administered liquid TCM formulae for the treatment of ADHD and ASD.

Hospital Leaders Explore the Future of Insulin Management at Glytec’s Conference on Glycemic Innovation and Collaboration

Retrieved on: 
Tuesday, July 26, 2022
FDA, Diabetes, Data Management, Technology, Practice Management, Pharmaceutical, General Health, Medical Devices, Hospitals, Other Technology, Biotechnology, Science, Software, Nursing, Research, Health, Division, Mayo Clinic Alix School of Medicine, Mayo Clinic, Wake Forest Baptist Medical Center, Diabetes, Diagnosis, Mortality, Blood, Centers for Medicare & Medicaid Services, Industry, High society, Internal medicine, Hospital, Research, CGMS-A, CMS, Disease, Section, Endocrine Society, FDA, Time, Hypoglycemia, Medical director, Patient, LinkedIn, Target, Insulin, Metabolism, Center, Medicare, Population, Nursing, Medical device, Pharmaceutical industry, Endocrine system, Endocrinology

Glytec , the only provider of cloud-based insulin management software across the continuum of care, today announced details about its annual conference on glycemic management and collaboration, Time To Target: The Future of Glycemic Management .

Key Points: 
  • Glytec , the only provider of cloud-based insulin management software across the continuum of care, today announced details about its annual conference on glycemic management and collaboration, Time To Target: The Future of Glycemic Management .
  • Attendees of this event will explore the latest trends in developing best-in-class glycemic management programs.
  • The focus on glycemic management has reached a tipping point in health systems across the country.
  • Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care.

Clinical Trial Patient Recruitment Services Market Report 2022: Development of Clinical Trials in the United States & Government Efforts to Improve Clinical Studies Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 12, 2022
Health, Clinical Trials, Collaborative partnership, Clinical trial, Degenerative disease, Acquisition, News, Investment, Value, Endocrine system, Profile, Adult, Mergers and acquisitions, Gaps, Weakness, Infection, COVID-19, Strategic management, Central nervous system, Market share analysis, Customer support, CAGR, Research, Growth, Use, Business Growth Fund, USD, Decision-making, Pharmaceutical industry, Retail, State, Child, Pain, Anesthesia

Based on Age Group, the market was studied across Adult and Child.

Key Points: 
  • Based on Age Group, the market was studied across Adult and Child.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.
  • It provides the idea of its revenue generation into the overall market compared to other vendors in the space.

Clinical Trials Site Management Organizations Market Report 2022-2027: Emerging Need for Outsourced Site Management Organizations Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, July 11, 2022
Health, Clinical Trials, Cardiology, Strategic management, Mergers and acquisitions, COVID-19, News, Market share analysis, Pain management, Regulation, Weakness, Value, CNS, Investment, Site management organization, Collaborative partnership, Customer support, Endocrine system, CAGR, Business Growth Fund, Use, USD, Acquisition, Decision-making, Gaps, Organization, Component, Growth, Research report, Pharmaceutical industry, Retail, State, Oncology

This research report categorizes the Clinical Trials Site Management Organizations to forecast the revenues and analyze the trends in each of the following sub-markets:

Key Points: 
  • This research report categorizes the Clinical Trials Site Management Organizations to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Phase, the market was studied across Phase I, Phase II, Phase III, and Phase IV.
  • Based on Components, the market was studied across Onsite monitoring, Project management, Regulatory, and Site Management.
  • Based on Therapeutic Areas, the market was studied across Cardiology, CNS, Endocrine, Oncology, and Pain Management.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

1 in 50 Women Will Suffer From Parathyroid Disease

Retrieved on: 
Wednesday, July 6, 2022
People, Well, Kidney failure, Diagnosis, Surgeon, View, Patient, Arrhythmia, Heart, Hyperparathyroidism, Research, University, Tissue, Brain, Parathyroid gland, Anatomy, Chronic fatigue, Element, Blood, Disease, Mark (given name), Neck, Depression, Gastrointestinal tract, Calcium, Endocrine system, Human body, Kidney, Woman, Risk, Cancer, Parathyroid disease, Neoplasm, Exocrine gland, Parathyroid hormone, Busch Gardens, Human, Mammal, Hospital, Headache, Hypertension, Osteoporosis, Amnesia, PTH, Bone pain, Muscle, Eating, Multimedia, Medical imaging, Phosphorus, Pharmaceutical industry, Dentistry, EU

Hyperparathyroidism (parathyroid disease) is the most common condition of parathyroid glands, caused by the development of a tumor on one or more parathyroid glands.

Key Points: 
  • Hyperparathyroidism (parathyroid disease) is the most common condition of parathyroid glands, caused by the development of a tumor on one or more parathyroid glands.
  • In fact, the Norman Parathyroid Center cites that 1 in 50 women will suffer from parathyroid disease at some point in their lives.
  • The surgeons at the Norman Parathyroid Center are by far the most experienced parathyroid surgeons in the world performing 70+ parathyroid operations per week.
  • Located in Tampa, Florida, the Norman Parathyroid Center is the leading parathyroid gland tumor treatment center in the world, performing nearly 3,800 parathyroid operations annually.

Sparrow Pharmaceuticals Presents Clinical Trial Data Analyses on HSD-1 Inhibitor SPI-62 at the Endocrine Society (ENDO) 2022 Annual Meeting

Retrieved on: 
Tuesday, June 14, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, ENDO, Cortisol, Steroid, Potent, Liver, Medication, UFC, ACTH, Â, Autoimmunity, Endocrine system, Brain, Cortisone, Endocrinology, Patient, Disease, Rheumatology, CSO, Prednisolone, Tissue, Polymyalgia rheumatica, Pharmaceutical industry, Medical imaging, Pig

Researchers examined glucocorticoid changes in healthy adults after administration of Sparrows lead therapeutic candidate, SPI-62, a HSD-1 inhibitor.

Key Points: 
  • Researchers examined glucocorticoid changes in healthy adults after administration of Sparrows lead therapeutic candidate, SPI-62, a HSD-1 inhibitor.
  • In fact, studies have shown that UFC normalization doesnt correlate with clinical endpoints in patients with Cushings syndrome.
  • The study analyzed historical clinical trial data to better characterize how SPI-62 impacts cortisol levels and the bodys homeostatic response to those changes.
  • To learn more about Sparrow Pharmaceuticals and its clinical pipeline, visit the website at www.sparrowpharma.com .

Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022

Retrieved on: 
Monday, June 13, 2022
ENDO, Maintenance, OLE, Lead, Data, Oles, Doctor of Philosophy, Trinity Medical Sciences University, ULN, Growth factor, Nasdaq, Physician, Endocrine system, FACE, Neurosurgery, Patient, OOC, Safety, Oregon Health & Science University, RCT, Overalls, Oregon Health Plan, FRCPC, Degenerative disease, Mayo Clinic, DPC, SRL, Pharmaceutical industry, Acromegaly, Endocrinology, MD

As a practicing endocrinologist, I believe that these data should give physicians more insights into the long-term benefit of Mycapssa for eligible patients.

Key Points: 
  • As a practicing endocrinologist, I believe that these data should give physicians more insights into the long-term benefit of Mycapssa for eligible patients.
  • As the first orally administered SRL approved for appropriate patients, OOC may represent a favorable option for maintenance therapy.
  • The MPOWERED trial was a global, randomized, open-label and active-controlled, 15-month trial intended to support approval of Mycapssa in the European Union.
  • At the end of the RCT phase patients were provided the option to continue into an open label phase and receive Mycapssa.

Recordati Rare Diseases Announces Several Scientific Abstracts to Be Presented at the Upcoming Endo Society Annual Meeting

Retrieved on: 
Wednesday, June 8, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, ENDO, QT interval, Plasma, Dizziness, Efficacy, Quality of life, Serum, Vomiting, ECG, Hypokalemia, Uncertainty, Hyperandrogenism, Infection, Barrow Neurological Institute, Headache, Advertising, Edema, Awareness, Half-life, Hypotension, Endocrine system, Hypoglycemia, Phase, Diagnosis, MD, Adrenal insufficiency, Patient, Degenerative disease, Hypertension, Nausea, Abdominal pain, Arrhythmia, Symptoms of COVID-19, Adrenocorticotropic hormone, Disease, Incidence, Androgen, Pituitary adenoma, Adult, Research, CYP3A4, Fatigue, Titration, Nature, ACTH, FDA, Mortality, CYP2B6, Risk, Magnesium, Lactation, QT, LINC, Pharmaceutical industry, Medical imaging, Birth control, Osilodrostat, Safety

Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be presented onsite at the ENDO 2022 annual meeting being held in Atlanta, Georgia from June 11 14, 2022.

Key Points: 
  • Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be presented onsite at the ENDO 2022 annual meeting being held in Atlanta, Georgia from June 11 14, 2022.
  • For more information visit www.isturisa.com
    About Recordati Rare Diseases Inc.
    Recordati Rare Diseases Inc. is a biopharmaceutical company committed to providing often-overlooked orphan therapies to the underserved rare disease communities of the United States.
  • Recordati Rare Diseases mission is to reduce the impact of extremely rare and devastating diseases by providing urgently needed therapies.
  • We work side-by-side with rare disease communities to increase awareness, improve diagnosis and expand availability of treatments for people with rare diseases.